Imaging of tumors using a specific PET scan agent
In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
This study is testing a new PET scan agent to see if it can help find and understand tumors in patients with different blood cancers and solid tumors.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05093335 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the uptake of the imaging agent [68Ga]-pentixafor in patients with various hematologic malignancies and solid tumors through PET/CT scans. It focuses on individuals with conditions such as non-Hodgkin lymphoma, multiple myeloma, and specific histiocytic neoplasms. The study will include treatment-naïve, therapy-refractory, or relapsed patients to assess the effectiveness of this imaging technique in identifying tumor presence and characteristics. A total of twenty patients will be enrolled based on specific eligibility criteria.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with treatment-naïve or relapsed blood cancers or specific solid tumors.
Not a fit: Patients with non-malignant conditions or those who have already received extensive treatment for their cancers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of tumor imaging, leading to better diagnosis and treatment planning for patients with hematologic and solid tumors.
How similar studies have performed: Other studies using similar imaging agents have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included: * Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) or Non-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantle cell lymphoma; and measurable disease according to Lugano criteria or * Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD) * MGUS/SMM or MM according to IMWG definitions * Solid tumors, such as lung cancers, meningioma, adrenocortical neoplasms including cortisol-producing adenomas or high suspicion for tumor, such as in patients with Cushing's disease. * Age ≥18 * Negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards \& Guidelines) from assays obtained \<2 weeks prior to study enrollment/intervention; or negative urine pregnancy test performed on the day of intervention * MSKCC patients Exclusion Criteria: * Breast-feeding * History of renal functional disorders (chronic kidney disease with eGFR\<30) * Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Where this trial is running
New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Anton Nosov, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Anton Nosov, MD
- Email: nosova@mskcc.org
- Phone: 212-639-8575
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.